

Date: 14/02/2020

To,  
**BSE Limited,**  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai-400001

**Sub: - Outcome of the Board Meeting held on 14<sup>th</sup> February, 2020**

**Company Scrip Code: 532167**

Dear Sir,

Pursuant to the provisions of Regulation 30 of the SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015, please note that the Board in its meeting held on 14<sup>th</sup> February, 2020 has considered and approved the following business:

1. Appointment of **Mr. Bhawani Shankar Goyal** as additional cum Managing Director of the company with immediate effect.
2. Un-audited Financial Results of the Company along with Limited Review Report for the quarter and Nine Months ended on 31<sup>st</sup> December, 2019.

Further, it is hereby confirmed that **Mr. Bhawani Shankar Goyal** is not debarred from holding the office of the Director by virtue of any SEBI order or any other such authority.

Furthermore, details required under regulation 30 of the Listing Regulations read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated 09<sup>th</sup> September, 2015 are given in enclosed **annexure-A**.

The aforesaid board meeting commenced at 04:30 P.M. and concluded at 05:40 P.M.

This is for your information and record.

Thanking You,

Yours faithfully,  
For **Omkar Pharmachem Limited**



(Parminder Sharma)  
Director  
DIN-00176300  
House No. 65, I Block Near  
Gurudwara Kutia Sahib B.R.S Nagar,  
Ludhiana-141012 Punjab

Enc: a/a

## Annexure-A

### Brief profile of the Managing Director

Name of Managing Director	Mr. Bhawani Shankar Goyal
Date of Appointment	14 February, 2020
Brief Profile	<b>Mr. Bhawani Shankar Goyal</b> aged 39 years holds Bachelor Degree in Commerce from Maharshi Dayanand University Rohtak Haryana and having vast experience of more than 16 years in the area of Accounts and Business Administration.
Terms of appointment	5 Years and others as mentioned in the appointment letter.
Relationship between Directors	<b>Mr. Bhawani Shankar Goyal</b> is not related with any directors of the company.
Reason for Change	Due to sudden and sad demise of <b>Mr. Anurag Sharma</b> former Managing Director of the Company.



# ॐ Omkar Pharmachem Ltd.

## Statement of Standalone Unaudited Financial Results for the Quarter & Nine Months ended on 31st December, 2019

(Rs. in lakhs except per share data)

Sr.	Particulars	Quarter Ended on			Nine Months Ended on		Year Ended On
		31-12-2019	30-09-2019	31-12-2018	31-12-2019	31-12-2018	31-03-2019
		(unaudited)	(unaudited)	(unaudited)	(unaudited)	(unaudited)	(audited)
	<b>Part-I</b>						
1	<b>Income from operations</b>						
	a) Net Sales/ Income from Operations	0.00	0.00	0.00	0.00	0.00	0.00
	b) Other Operating Income	0.00	0.00	0.00	0.00	0.00	0.00
	Total	0.00	0.00	0.00	0.00	0.00	0.00
2	Other Income	0.00	0.00	0.00	0.00	0.00	0.00
3	<b>Net Total Income</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
4	<b>Expenses</b>						
	a) Cost of material consumed	0.00	0.00	0.00	0.00	0.00	0.00
	b) Purchase of Stock-in-trade	0.00	0.00	0.00	0.00	0.00	0.00
	c) Changes in Inventories of Finished Goods, WIP and Stock-in trade	0.00	0.00	0.00	0.00	0.00	0.00
	d) Employee benefits expenses	4.07	3.33	4.35	11.54	14.95	19.06
	e) Finance Costs	0.00	0.00	0.00	0.00	0.04	3.74
	f) Depreciation and Amortization Expenses	0.05	0.04	0.09	0.14	0.26	0.35
	g) Other Expenses	0.96	1.28	1.29	7.77	8.55	18.91
	Total Expenses	<b>5.08</b>	<b>4.65</b>	<b>5.73</b>	<b>19.45</b>	<b>23.80</b>	<b>42.06</b>
5	<b>Profit(Loss) from operations before Exceptional Items &amp; Taxes (3-4)</b>	<b>(5.08)</b>	<b>(4.65)</b>	<b>(5.73)</b>	<b>(19.45)</b>	<b>(23.80)</b>	<b>(42.06)</b>
6	Exceptional items	0.00	0.00	0.00	0.00	0.00	0.00
7	<b>Profit(Loss) before Tax (5+6)</b>	<b>(5.08)</b>	<b>(4.65)</b>	<b>(5.73)</b>	<b>(19.45)</b>	<b>(23.80)</b>	<b>(42.06)</b>
8	Tax Expense	0.00	0.00	0.00	0.00	0.00	(0.04)
9	Profit(Loss) for the period (7-8)	<b>(5.08)</b>	<b>(4.65)</b>	<b>(5.73)</b>	<b>(19.45)</b>	<b>(23.80)</b>	<b>(42.02)</b>
10	Other Comprehensive Income (Expense)	0.00	0.00	0.00	0.00	0.00	0.00
11	Total Comprehensive Income for the period (9+10)	<b>(5.08)</b>	<b>(4.65)</b>	<b>(5.73)</b>	<b>(19.45)</b>	<b>(23.80)</b>	<b>(42.02)</b>
12	Paid up Equity Share Capital (Face Value Rs. 10/-each)	1008.37	1008.37	1008.37	1008.37	1008.37	1008.37
13	Reserves excluding Revaluation Reserved as on 31st	(138.27)	(138.27)	(96.26)	(138.27)	(96.26)	(138.27)
14	Earning Per Share(before & after extraordinary items)(of Rs. 10 each)(not annualised) Basic and diluted Rs.	<b>(0.0504)</b>	<b>(0.0461)</b>	<b>(0.0568)</b>	<b>(0.1929)</b>	<b>(0.2360)</b>	<b>(0.4167)</b>

**Notes:**

- The above results have been reviewed by the audit committee & approved by the Board of Directors at their respective meetings held on 14th February 2020.
- Corresponding previous period figures are regrouped/rearranged wherever necessary, to make them comparable.
- The IND-AS regarding segment reporting is not applicable to the company as there is no segment.
- Reserves includes reserves and surplus.

By order of the Board



**Parminder Sharma**

Director

DIN: 00176300

House No-65, I Block, Near Gurudwara

Kutia Sahib, B.R.S Nagar, Ludhaian-141012 PB

Date : 14-02-2020  
Place: Ahmedabad






Limited Review Report to The Board of Directors of **Omkar Pharmachem Limited** for quarter and nine months ended on 31<sup>st</sup> December, 2019

We have reviewed the accompanying statement of unaudited financial results of **Omkar Pharmachem Limited** for the quarter and nine months ended on 31<sup>st</sup> December, 2019. This statement is the responsibility of the Company's management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and; thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our notice that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure





Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.



For, Rajesh J. Shah & Associates  
Chartered Accountants  
FRN 108407W

(Rajesh J. Shah)  
Partner

Place: Ahmedabad  
Date : 14/02/2020

UDIN: **20040268AAAAAI2018**